Abstract
In situ carcinomas of the breast constitute 15% to 30% of all newly diagnosed breast cancer cases. Although the concept of carcinoma in situ has been proposed for a long time, there is still a great controversy regarding the screening, diagnosis and treatment. This article attempts to reach some consensus on the management of ductal carcinoma in situ and lobular carcinoma in situ and provide references for clinicians in the following aspects: definition and classification, natural history and prognosis, diagnosis, local and systemic treatment for primary carcinoma in situ, recurrence risk and treatment approaches for recurrent cancers.
| Original language | English |
|---|---|
| Pages (from-to) | 942-947 |
| Number of pages | 6 |
| Journal | Zhonghua zhong liu za zhi [Chinese journal of oncology] |
| Volume | 38 |
| Issue number | 12 |
| DOIs | |
| State | Published - 23 Dec 2016 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Chinese expert consensus on the diagnosis and treatment of breast carcinoma in situ'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver